Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

86.00CHF
21 Aug 2019
Change (% chg)

CHF0.00 (+0.00%)
Prev Close
CHF86.00
Open
CHF86.00
Day's High
CHF86.00
Day's Low
CHF86.00
Volume
168
Avg. Vol
9,743
52-wk High
CHF141.90
52-wk Low
CHF76.10

Select another date:

Mon, Jul 1 2019

BRIEF-Cosmo Pharmaceuticals: Canadian Agency Approval Of Eleview

* ELEVIEW(R) WILL BE COMMERCIALIZED IN CANADA BY PENDOPHARM (DIVISION OF PHARMASCIENCE INC.) UNDER AN EXISTING LICENSE AND SUPPLY AGREEMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Announces Publication Of Positive Review Of Aemcolo

* ANNOUNCED TODAY PUBLICATION OF A REVIEW OF AEMCOLO IN A CLINICAL INVESTIGATION THAT HIGHLIGHTS ITS SAFETY AND EFFECTIVENESS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-FDA Accepts NDA Filing For Cosmo Pharmaceuticals' Remimazolam

* FDA ACCEPTS FILING OF NDA FOR REMIMAZOLAM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Announces Distribution Agreement And Further Collaboration Agreement

* NEW EXCLUSIVE DISTRIBUTION AGREEMENT FOR ELEVIEW WITH MEDTRONIC IN THE US, CHINA AND SOUTH AMERICA

BRIEF-Cosmo Pharmaceuticals: FDA Allowance Of IND Application For CB-03-10

* FDA Allowance Of IND Application For CB-03-10 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals: Worldwide Distribution Agreement Of AI Device In Colonoscopy With Medtronic

* COSMO PHARMACEUTICALS ANNOUNCES REVOLUTIONARY ARTIFICIAL INTELLIGENCE DEVICE IN COLONOSCOPY TO DETECT LESIONS AND WORLDWIDE DISTRIBUTION AGREEMENT WITH MEDTRONIC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals Announces Submission Of Remimazolam NDA To FDA

* ANNOUNCES SUBMISSION OF REMIMAZOLAM NDA TO FDA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Cosmo Pharmaceuticals FY Oper Loss Widens To EUR 16.6 Mln

* FY REVENUE EUR 65.6 MILLION COMPARED TO EUR 67.2 MILLION IN 2017

BRIEF-Cosmo Pharmaceuticals Announces Denial Of Methylene Blue MMX Appeal

* COSMO PHARMACEUTICALS ANNOUNCES DENIAL OF METHYLENE BLUE MMX APPEAL AND BEGINNING OF ACTIVITY TO START SECOND PHASE III TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: